Corporate Office: 13/14, Aradhana IDC, Near Virwani Industrial Estate, Goregaon (East),

Mumbai - 400 063.

Tel.: +91-22-4252 2200 / Fax: +91-22-4252 2380

URL http://www.sumichem-india.co.in

SCIL/SEC/2023 4th February, 2023

To, BSE Limited, Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001

The National Stock Exchange of India Listing Department, Exchange Plaza, Bandra Kurla Complex Bandra East, Mumbai - 400 051

Dear Sirs,

## Sub: Investor Presentation on Financial Results for the Quarter and nine months ended 31st December, 2022

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith investor presentation on the Financial Results of the Company for the quarter and nine months ended 31st December, 2022.

Kindly do the needful to display the same on your website.

Thanking you,

Yours faithfully, For Sumitomo Chemical India Limited

Pravin D. Desai Vice President and Company Secretary

Encl: a/a



# Sumitomo Chemical India Limited





Investor Presentation

## Safe Harbour



This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Sumitomo Chemical India Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.


This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.


Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.




## Performance Highlights – Quarter & YTD








Gross Profit (Rs. Crs) & Gross Profit Margin (%)




EBITDA (Rs. Crs) & EBITDA Margin (%)




PAT (Rs Crs)




Revenue (Rs Crs)




Gross Profit (Rs. Crs) & Gross Profit Margin (%)



EBITDA (Rs. Crs) & EBITDA Margin (%)



PAT (Rs Crs)



## Performance Highlights – 9MFY23



#### **Key Highlights**

- ✓ At the industry level, overall demand, particularly in the domestic market, was sluggish during the quarter, primarily as a result of a delay in sowing due to the extended monsoons and an increase in channel inventory as a result of a slower offtake during the kharif season. The inventory levels were also high, as the level of pest infestation was relatively low
- ✓ Our domestic volumes growth during the quarter were largely benign due to the challenging environment. However, the decline in demand was partially offset by improved price realizations. Sharp decline in revenue from fungicide segment resulted into modest topline growth
- ✓ The export growth continues to remain robust, while there are some signs of slowdown in Latin America due to high channel inventory. Recent capacity expansion investments should help sustain this encouraging trend. The export business has witnessed growth of 39% y-o-y in 9MFY23
- √ 4 insecticide, 1 fungicide, 1 metal phosphide and 3 PGR products launched during 9MFY23
- ✓ Our efforts to enhance our product mix, revamp our distribution reach and scaling up our capacities positions us to deliver consistent results in the future
- ✓ The company is taking steps to boost growth in both domestic and international markets. In recent years, we have prioritized filling in the gaps in our portfolio, particularly for certain crops and pests. We are optimistic that these efforts will result in steady future growth

#### **New Product Launches**

Company launched 3 unique proprietary 9(3) products — **Sumi Blue Diamond, Pyclome and Danitol NXT** during the National Level and
Regional Level Trade Channel Partners' Meeting



The company has **recently received registrations for 2 unique proprietary 9(3) products** and is in process of commercially launching these products in the market


## Consolidated Profit & Loss Account Statement – Quarter & YTD




Particulars (Rs. Crs)	Q3 FY23	Q3 FY22	YoY	Q2 FY23	QoQ	9MFY23	9MFY22	YoY
Revenue from Operations	753.7	707.2	7%	1,121.7	-33%	2,860.8	2,399.5	19%
COGS	487.3	441.5	*	696.7		1,823.2	1,496.6	 
Gross Profit	266.4	265.7	0%	424.9	-37%	1,037.6	902.9	15%
Gross Profit %	35.3%	37.6%	-223 bps	37.9%	-254 bps	36.3%	37.6%	-136 bps
Employee Expenses	52.3	51.8	 	54.3		163.9	151.5	
Other Operating Expenses	93.6	87.3	 	92.6	 	287.7	260.5	 
Operating EBITDA	120.4	126.5	-5%	278.0	-57%	586.0	491.0	19%
EBITDA Margin	16.0%	17.9%	-191 bps	24.8%	-881 bps	20.5%	20.5%	2 bps
Other Income	13.2	6.2	 	10.5	 	28.4	19.4	
Depreciation	11.4	11.4		15.2		37.8	33.4	
EBIT	122.2	121.3	1%	273.4	-55%	<i>576.6</i>	477.0	21%
EBIT Margin	16.2%	17.1%	-93 bps	24.4%	-815 bps	20.2%	19.9%	27 bps
Interest	1.3	1.6	 	1.4	 	4.0	5.4	 
Profit Before Tax	120.9	119.7	1%	272.0	-56%	<i>572.6</i>	471.6	21%
PBT Margin	16.0%	16.9%	-88 bps	24.2%	-821 bps	20.0%	19.7%	36 bps
Tax	30.4	30.7	 	70.5	 	142.5	122.7	 
Net Profit	90.5	88.9	2%	201.5	-55%	430.1	348.9	23%
Net Profit Margin	12.0%	12.6%	-57 bps	18.0%	-596 bps	15.0%	14.5%	49 bps
Other Comprehensive Income	-1.2	0.5	T	0.3		1.6	0.1	
Total Comprehensive income for the period	89.3	89.4	0%	201.7	-56%	431.7	349.0	24%


## Revenue Breakup – YTD








#### **Segment Breakup**



#### **Bulk & Branded**



<sup>\*</sup> Animal Nutrition Division (AND) and Environmental Health Division (EHD)

## Consolidated Working Capital Movement



Particulars (Rs. Crs)	Dec-22*	Sep-22*	Change (Dec-22 to Sep-22)	Mar-22*	Change (Dec-22 to Mar-22)	Dec-21*	Change (Dec-22 to Dec-21)
Inventory (A)	750.4	818.2	-67.8	937.8	-187.4	696.6	53.8
Inventory Days (Inventories/ COGS* No. of days in period) (i)	113	110		179		128	
Trade Receivables (B)	1,035.7	1,185.3	-149.6	843.1	192.6	917.1	118.6
Trade Receivables Days (Trade Receivables / Revenue*No. of days in period) (ii)	100	101		100		105	
Trade Payables (C)	473.9	549.5	-75.6	517.2	-43.3	509.1	-35.2
Trade Payables Days (Trade Payables/ COGS*No. of days in period) (iii)	71	74		99		94	
Other Financial Liabilities (D)	436.4	512.4	-76.0	399.7	36.7	424.9	11.5
Other Financial Liabilities Days (Other Current Liabilities / Revenue*No. of days in period) (iv)	42	44		48		49	
Net Working Capital (A+B-C-D)	875.8	941.6	-65.8	864.0	11.8	679.7	196.1
Net Working Capital Days (i + ii – iii – iv)	99	94		133		91	

#### **Key Highlights**

- ✓ Continue to maintain lower inventory as compared to previous quarters on back of smoothening of input supply chain channels and decrease in input cost
- ✓ Focused efforts towards improving collections Collection during 9M FY23 of ~Rs. 2,989 crores as compared to Rs. 2,512 crores during 9M FY22, increased by 19% yoy
- ✓ Cash, Cash Equivalents and Liquid investments of ~Rs. 892 crores as on 31st December 2022



## Overview of our Parent Company



#### **About Sumitomo**

- ✓ Sumitomo started business in Japan in early 16th Century (400 years+)
- Currently several Sumitomo founded companies operate as independent listed companies with widespread shareholding and run by its professional boards
- ✓ Even today, all Sumitomo companies continue to follow basic business philosophy and ethical practices of Sumitomo

#### About Sumitomo Chemical Company Limited, Japan (SCC)

- ✓ SCC was founded in 1913 and undertakes several chemical related businesses as an independent listed company
- ✓ SCC is a leading Japanese research driven diversified chemical company listed on the Tokyo Stock Exchange with consolidated sales revenue of more than US\$ 22.5 bn
- ✓ Offers diverse range of products globally in 5 business sectors: petrochemicals, energy and functional materials, IT-related chemicals and materials, pharmaceuticals and health and crop sciences sector;
- ✓ Follow principles of 'JIRI RITA' which means balance between society benefits and corporate profits; Sustainability is very high priority and SCC received Ecovadis Gold rating
- ✓ SCC holds 12,600+ Patents of which ~34% are in Health & Crop Science

#### SCC's Health and Crop Science Sector - Undivided Focus for Leadership in India

- √ Health & Crop Sciences Sector Revenue of more than US\$ 3.8 bn
- ✓ Leading R&D spenders globally among agro-solution players
- ✓ Strong pipeline of Agro-Solutions and Environmental Health products with very high business potential of ~US\$1.4 -\$1.8 bn
- ✓ SCC recently acquired Nufram's distribution in Latin America thereby gaining leadership position in Latin America Generics Market Segment
- ✓ SCIL is flagship entity of SCC group focusing on high potential Indian market; only TG grade manufacturing site outside Japan and part of SCC's growth strategy
- ✓ SCC is **proud of SCIL's achievement** so far and confident of its growth potential
- ✓ SCC will continue to support SCIL to achieve market leadership position in Indian market

## Sumitomo Chemical India Ltd.

- Company Overview

SCIL - Vision & Mission

Journey to 13x Growth in India

Formidable Player in the Indian Agrochemicals Space

Diversified & De-risked Portfolio Across the Agro-Chem Value Chain Strong Brand and Well-Entrenched Distribution Network

Strategically Located Manufacturing Facilities

Strong Focus on R&D, Process Innovation and Safety, Health and Environment (SHE)

Autonomous Board with Vast Industry Experience

Growth Strategies

### SCIL - Vision & Mission





#### Vision:

- To be a trusted market leader in Indian cropprotection sector
- To develop a vibrant corporate culture
- Endeavor to achieve success and sustainability through innovation & excellence

#### **Core Values:**

- Innovation
- Excellence
- Integrity
- Respect & value all stakeholders
- Customer focus
- People focus
- Sustainability





#### Mission

#### **Marketing and Sales:**

- Further penetration into Indian market & take leadership; expand exports
- Strengthen Sales Force, Distribution and Product Portfolio

#### Manufacturing:


- Supplying the most competitive products with safe and stable operation and meet demand
- Strengthen Procurement Power
- Expand Manufacturing Functions

#### **Management & Support:**

- Establishing the most efficient organization to support business growth and alignment with SCC
- Develop administrative efficiency while ensuring internal controls
- Full & Strict Compliances
- Value Creation for all stakeholders

## Journey to 13x Growth in India in last 12 years





## Formidable Player in the Indian Agrochemicals Space



5
Manufacturing
Facilities

14
Technical Actives

16,000+
Direct Distributors
& 60+ Depots

200+ 700+

Brands

SKUs

25+/200+


Patents / Registrations

1,750+

**Employees** 

	Product Name	Product Category	indicative Use
	Glyphosate	Herbicide	Tea Gardens, non-cropped
ts	Profenophos	Insecticide	Cotton, Soya bean
Key Products	Dantotsu	Insecticides	Vegetables
0	Tebuconazole	Fungicides	Wheat, Soya bean, Chilli
> -	Progibb	Plant Growth Regulator	Citrus Fruits
×	Aluminum Phosphide	Fumigant	Warehousing of Food Grains
	Chlorpyriphos	Insecticide	Paddy, Beans, Gram
	DL-Methionine	Animal Nutrition	Poultry


Grown 13X+\* over FY11-22



<sup>\*</sup>On an organic basis, grown 6X+

## Diversified & De-risked Portfolio Across the Agro-Chem Value Chain





- ✓ Greater focus on high growth, stable and high profitable segments such as Herbicides, PGR, Bio-rational products
- ✓ Increasing contribution from PGR segment and offerings for both Kharif and Rabi crops to reduce seasonality in the business
- ✓ One of the highest proportion of environmentally-friendly products in the Industry

- ✓ Top 10 products contributes less than 45% of Total Revenue
- √ No product / molecule contributes more than 16% of Total Revenue
- ✓ Diversified across key crops Concentrated efforts now on fruits & vegetables, paddy and other high growth segments

## Strong Brand and Well-Entrenched Distribution Network



- ✓ Strong brand with market leading position across various product categories
- ✓ **Dual brand portfolio** can offer products at all price points serving multiple customer sub-segments
- ✓ In-depth knowledge of own research products, proven go-to-market strategy and deep farmer connect facilitates launch of Speciality products
- ✓ On-field demonstration of products, training of farmers in using the products, building awareness among stakeholders in relation to the products
- ✓ Pan-India distribution network ensures strong presence with both retailers and farmers and on-time feedback mechanism
- Scale and diversity of product offerings lead to superior bargaining power with distributors and provides one-stop solution for farmers
- Expanded teams for strategic marketing, demand generation, product development and regulatory affairs to focus on future growth



23 States



16,000+

**Distributors** 



4.4 million+

Farmer Connect through

1,500+

Field / Market Development
Officers



**60+** Depots




**~40,000**Dealers



~600

Sales Team



## **Expanding Brand Visibility and Connect**


















- More than 1,500+ Relationship managers connecting to 4.4 million+ farmers throughout crop cycle
- Over 200 brands covering maximum of crops and pest segments
- 16,000+ distributors, 40,000+ dealers and 60 Depots help in expanding brand visibility and connect
- More than 600+ Qualified and skilled managers in Sales, Marketing and customer support
- Company with 20+ mega brands with high brand recall
- Healthy geographical Brand coverage throughout India including North East and J&K
- Optimum use of advertising media with increased Digital Platforms presence







## Digital Marketing Initiatives



#### Develop "Digital Marketing" as a parallel support to Traditional marketing system leading to improved sales.

✓ Our Digital Assets: 23 websites, engaged with 17.2 million consumers in 2021-22.











- ✓ Successful campaign to introduce the QR codes of <a href="http://www.sumitomoproducts.com/">http://www.sumitomoproducts.com/</a> to the retailers and farmers.
- ✓ Video based campaigns to increase awareness among farmers and disseminate information on necessary precautions to stop the spread of COVID 19.



#### More than 31,000 subscribers





Conducted 100s of YouTube, Facebook, Google, Zoom Video Live sessions in 2021-22




15 Digital Launch programs of Taboli across India to introduce the product to distributors & retailers



- ✓ More than 5,000 downloads
- ✓ Rating 4.5

## Digital transformation & SAP Implementation





## Strategically Located Manufacturing Facilities



#### Connectivity to Major Cities and Proximity to Main Highways, Ports Reduces Logistic Time and Costs



Plant Location	Area (acres)	Segment Served	Product Manufactured
Bhavnagar	~58	Manufacturing of Technical Grade Pesticides and Formulations	Chlorpyriphos, Profenophos,
Gajod	~120	Production and manufacturing of Metal Phosphides, Sulphur WDG and other WDG formulations	Glyphosate, Tebuconazole Tech, Quinalphos, Imidacloprid, Thiacloprid,
Tarapur	~5	Production and manufacturing of Active Ingredients	Acetamiprid, Byspyribac Sodium, Fluroxypyr, Aluminium Phosphide, Zinc
Vapi	~6	Formulation & Packaging	Phosphide, Sulphur WDG, Fenpropathrin
Silvassa	~3	Formulation of Glyphosate and Other Speciality Products	Formulations for above TG products and several other speciality and generic products

- Overall Optimal capacity utilization generally
- Continues investments to enhance capacity as per the forecasted demand (similar to the trends followed in past)
- Recently acquired additional land at Dahej and Bhavnagar for future projects

## Capex Plans



# Regular Capex Rs. 70-75 crore p.a.

Maintenance capex

Capacity enhancements for existing products in line with projected demand

Infrastructure enhancements for supporting future growth

Efficiency improvement projects and safety enhancement

Sustainability initiatives, full compliance with environmental norms & renewable energy projects

Trials and registrations for future pipeline products

#### Additional Capex Rs. 120 crore over 2 years for 5 products

To manufacture additional proprietary technical grade active ingredients products for our parent company SCC Japan and our global affiliates

**5 products have been approved** in-principle for supply to SCC and several others are in pipeline

Projects are being set-up at our existing sites.

Target commercialization over next 1 year

Revenue potential of these 5 products on the above capex is Rs. 200 crore to Rs. 250 crore p.a.

Estimated margins are in line with current margins earned by SCIL for similar projects

These products have growing global demand.
Potential to add further capacities and
additional products in medium to long term

#### **Research & Development**



Indian R&D team is working on manufacturing several off-patent products for Domestic as well as Exports to global affiliates including high growth regions such as Latin America, Africa and Asia Pacific which will entail additional capex and is under evaluation

#### **Future Expansion Plans**



Signed and registered agreements to buy 2 additional land parcels and transfer process is expected to be completed soon

- ~20 acre privately owned land parcel adjoining our existing Bhavnagar site
- ~50 acre privately owned land parcel at a prime location at Dahej within PCPIR Zone


One project for a very important global proprietary product began commercial production recently and the second project involving multiple products is expected to begin commercial production in Q1 FY23-24

## Strong Focus on R&D and Process Innovation



#### **End-to-End Product Development Capabilities**

- ✓ 3 fully equipped, DSIR approved R&D labs located at Mumbai, Bhavnagar and Gajod capable of synthesis, technical product and formulation development
- ✓ R&D Team comprises of 75+ qualified and dedicated engineers & scientists
  of which 10+ are PhDs with more than 15 years of Experience
- ✓ 25+ patents granted across various geographies; 9 applications filed
- ✓ Product Pipeline
  - Multiple products coming from initiatives
  - Global Speciality Proprietary products to be launched in India
  - New combination products / pre-mixtures currently under development for domestic and exports
  - Off-patent products under development for domestic and exports
  - Technical products approved for manufacturing and exports
- ✓ R&D facilities to gain capability for creating new processes and new combinations using SCC Japan's chemistries which would help improve production processes and efficiency



## Thrust on Safety, Health and Environment (SHE)



# Quality Certifications Ensure Consistent product quality and healthy working environment at manufacturing sites



ISO:9001:2015, ISO-14001:2015 and OHSAS18001:2007 for the manufacturing sites at Bhavnagar, Gajod, Tarapur and Silvassa; ISO:9001:2015 at Vapi



A8000 Certification for Social Accountability in Bhavnagar and Gajod



Efforts focused on reducing effluent load and effluent treatment cost, for staying innovative and competitive in the market



The quality of the products is maintained and upgraded to the applicable national and international standards through rigorous pursuit of Six Sigma initiative



Focused on energy conservation and energy cost reduction: 50% of total power requirement through wind and solar power generation plants



Expanding solar power plant capacity in line with towards green energy would also help in reducing dependence on outsourced power as well as in energy cost reduction



3R Principle: Recovery – Recycle – Reuse



Safety audit, training programmes and other safety management processes and programmes are carried out/conducted at regular intervals



All the manufacturing and warehousing sites of the Company are covered by safety audit



#### **Abiding by SCC Japan's EHS Policies**



Dr. Vikram Sarabhai award for developing green technology from department of Science and Technology, Government of Gujarat



Certificates of appreciation received ten times from jointly by Gujarat Safety Council and Dish



Government of Gujarat for achieving 10 lakh accident free man-hours



Certificates of merits received from jointly by Gujarat Safety Council and Dish Government of Gujarat for achieving 20 lakh accident free man-hours



Certificates of honour received two times jointly by Gujarat Safety Council and Dish Government of Gujarat for achieving 30 lakh accident free manhours

#### Focus on purity, quality and timely delivery of products to the customer

## Awards & Accolades





Jamnalal Bajaj Award for "Fair Business and Practices"



First ever president's gold shield for import substitution



First award for export of organic and inorganic chemicals



ICMA award for innovation and purposeful programs for social progress



First Sir P.C. Ray award for development of products and process with indigenous technology



Punjab Haryana Delhi Chamber of Commerce and Industries award for ethical business



Winner active ingredient trophy and certificate from M/s. Bayer



Trishul award for the excellent performance for exports in international markets



Global CSR award from SCC for one of our Integrated Village Development Programme



Shramveer award for improvement of product efficiency received from national level Delhi



Vishwakarma Rashtriya Puraskar received for process development



National Safety Award by Labour Ministry, Government of India for safety performance



Shramveer Award to employees from Labour Ministry, state level received six times



Shram Bhushan Award to employees received five times



Shram Ratna to employees, received seven times



Shram Shri award to employees received three times



Gujarat State Safety Certificate for safety commitment



CSR Award from Federation of Gujarat Industries

## Autonomous Board with Vast Industry Experience





**Dr. Mukul Govindji Asher**Chairman and Independent Director

- Professorial Fellow at Lee Kuan Yew School of Public Policy at the National University of Singapore
- Advisor to Govts in Asia on tax policy & pension reforms; and to multi-lateral institutions including IMF, Asian Development Bank, PFRDA of India, Govt of Gujarat, & World Bank
- Member of the panel to review Crawford School of Public Policy at Australian National University



Preeti Gautam Mehta
Independent Non-executive Director

 30 years of experience in corporate laws, foreign investment and collaborations, mergers and acquisitions and private equity investments, banking, franchising and hospitality



# Bhupendranath Bhargava Independent Non-executive Director

- Experience of over 50 years in areas including banking, project financing and credit rating
- Held directorship in several leading corporates and was on the advisory board of an independent regulatory body set up by the Government of India to work on reforms in telecommunications sector



# Ninad Dwarkanath Gupte Non-executive Director

#### For executive Birector

- Experience of 43 years in management of companies operating in fine chemicals, performance chemicals, industrial chemicals & agrochemicals
- Held senior positions at Excel Industries, BASF India, Herdillia Chemicals and worked as MD of Cheminova India and Agrocel Industries and as Joint MD of Excel Crop Care

## Autonomous Board with Vast Industry Experience





Hiroyoshi Mukai Non-executive Director

- Associated with Sumitomo Chemical Group for over 30 years
- Holds a bachelor's degree from the University of Osaka, Japan



**Tadashi Katayama Non-executive Director** 

- MBA from Vanderbilt University, U.S.A. and a Master's degree from Kyoto University in Japan
- Associated with Sumitomo Chemical, Japan since 1992 in the Health and Crop Science business unit in various positions



Masanori Uzawa
Non-executive Director

- MBA from University of Virginia, USA and a Bachelor's degree from the University of Tokyo in Japan
- Associated with Sumitomo Chemical, Japan and has experience of over 19 years in the areas of strategy, planning and business development for crop protection & other chemical businesses.



**Chetan Shantilal Shah Managing Director** 

- Commerce graduate from the University of Mumbai and holds a master's degree in Business Administration from North Rope University in the USA
- Over 43 years of industry experience in various leadership and senior management roles



Sushil Champaklal Marfatia

#### **Executive Director**

- Chartered Accountant with over 42 years of industry experience
- Worked with New Chemi Industries Limited for 33 years which was later merged with the Company

Board is supported by a strong and experienced management team associated with Company since long

## **Growth Strategies**





#### Continued Investment in R&D and Pipeline

- Aim to invest in seamless integration of R&D between SCIL and SCC units which would help improve our production processes, enhancing yields and efficiency
- Introduce new products as per market demand



#### **Capacity Expansion**

- Driving operational efficiencies maintaining highest safety standards and Responsible Care compliances
- Invest ~15% of consolidated EBITDA every year for upgradation of manufacturing facilities and capacity expansion to cater to strong domestic/global demand



#### Further Brand Development

- Investments for marketing of new and existing products and brands
- On-field demonstrations, training of farmers for building ground-level demand generation supported by digital marketing
- Extraordinary preparations for new product launches underway



#### **Product Pipeline**

- Multiple products coming from initiatives
- Global Speciality Proprietary products to be launched in India
- New combination products / pre-mixtures currently under development for domestic and exports
- Off-patent products under development for domestic and exports
- Technical products for manufacturing and exports



#### **Expand Export Business**

 Enhance exports in regions like Africa Leverage SCC's Global supply chain and marketing network to drive exports in Latin America, Asia and Europe

# Achieving Market Leadership in India

- Balanced portfolio of generic and speciality products
- Consolidate position as best agro-chemical marketer in India
- Strive for manufacturing excellence
- Set-up a strong management & team
- Lay the foundation for next generation leadership

Leverage expertise in successful product launches and capacity expansions to fuel future growth



# Financial Performance & Key Takeaways

Historical Performance Highlights

Key Takeaways

## Consolidated Balance Sheet



Assets (Rs. Crs)	Sep-22	Mar-22
Non-Current Assets (A)	590.2	487.6
Property, Plant and Equipment	379.3	349.6
Capital work-in-progress	22.5	21.1
Right to use an Asset	30.7	36.4
Other Intangible Assets	4.6	4.3
Intangible Assets under Development	16.6	14.1
Non-Current Financial Assets		
(i) Investments	0.1	0.1
(ii) Loans & other financial assets	104.2	30.8
Deferred tax Asset (net)	-	-
Non-Current tax Assets (net)	23.7	21.6
Other non-current Assets	8.4	9.5
Current Assets (B)	2,864.8	2,522.0
Inventories	818.2	937.8
Current Financial Assets		
(i) Investments	311.2	356.0
(ii) Trade receivables	1,185.3	843.1
(iii) Cash and cash equivalents	80.8	57.2
(iv) Bank balances other than (iii) above	218.0	21.9
(v) Loans	0.4	0.5
(vi) Other financial assets	114.8	174.5
Other Current Assets	136.1	131.0
Total Assets (A+B)	3,454.9	3,009.6

Equity & Liabilities (Rs. Crs)	Sep-22	Mar-22
EQUITY (A)	2,219.7	1,927.2
Equity Share Capital	499.1	499.1
Other Equity	1,720.6	1428.1
Non-current liabilities (B)	41.6	61.0
Non-Current Financial liabilities		
Lease Liabilities	17.2	24.7
Provisions	7.3	22.3
Deferred tax liabilities (net)	17.1	13.9
Non-current Tax Liabilities	-	-
Current liabilities (C)	1,193.6	1,021.4
Current Financial liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	549.5	517.2
(iii) Lease Liabilities	14.5	12.9
(iii) Other financial liabilities	512.4	399.7
Other current liabilities	54.6	79.8
Provisions	18.8	7.2
Current tax liabilities	43.8	4.7
Total Equity & Liabilities (A+B+C)	3,454.9	3,009.6

NIL borrowings

Cash, Cash Equivalents & Liquid Investments of ~Rs. 800 Crs as on 30<sup>th</sup> September 2022

<sup>1.</sup> Given the seasonality in the business, it is best monitored on an annual basis

<sup>2.</sup> Appointed date for merger of ECC and SCIL is 1st Apr'18

## Consolidated Cash Flow Statement




Cash Flow Statement (Rs. Crs)	Year ended 30-Sep-22	Year ended 30-Sep-21
Net Profit Before Tax	451.6	351.9
Adjustments for: Non-Cash Items / Other Investment or Financial Items	34.5	23.0
Operating profit before working capital changes	486.1	375.0
Changes in working capital	-105.6	41.5
Cash generated from Operations	380.5	416.4
Direct taxes paid (net of refund)	72.7	56.1
Net Cash from Operating Activities	307.8	360.3
Net Cash from Investing Activities	-223.2	-417.8
Net Cash from Financing Activities	-61.0	-51.9
Net Increase /(Decrease) in Cash and Cash equivalents	23.5	-109.4
Add: Cash & Cash equivalents at the beginning of the period	57.2	213.3
Cash & Cash equivalents at the end of the period	80.8	103.9

<sup>1.</sup> Given the seasonality in the business, it is best monitored on an annual basis since a significant portion of revenue & PAT is recorded in the first half of the year

## Historical Performance Highlights





<sup>1.</sup> Given the seasonality in the business, it is best monitored on an annual basis since a significate portion of revenue & PAT is recorded in the first half of the year

<sup>2.</sup> Appointed date for merger of ECC and SCIL is 1st Apr'18

## Consolidated Profit & Loss Account Statement



Particulars (Rs. Crs)	FY22	FY21	FY20	FY19	FY18
Net Revenue from Operations	3,064.6	2,644.9	2,424.8	2,228.4	1,912.9*
COGS	1,908.0	1,655.4	1,607.6	1,458.9	1,238.7
Gross Profit	1,156.6	989.5	817.2	769.6	674.2
Gross Profit %	37.7%	37.4%	33.7%	34.5%	35.2%
Employee Expenses	202.0	194.3	179.3	158.4	147.5
Other Operating Expenses	354.7	308.4	304.7	320.5	309.6
Operating EBITDA	599.9	486.9	333.2	290.7	217.1
EBITDA Margin	19.6%	18.4%	13.7%	13.0%	11.3%
Other Income	26.8	18.6	10.7	7.6	30.5
Depreciation	44.8	46.6	41.0	27.8	23.7
EBIT	581.9	458.9	302.9	270.5	223.8
EBIT Margin	19.0%	17.3%	12.5%	12.1%	11.7%
Interest	6.2	5.6	5.5	3.7	2.8
Profit Before Tax & Exceptional	575.7	453.3	297.4	266.8	221.0
Exceptional Item Gain / (Loss)**	0.0	-	-30.9	-7.0	-
Profit Before Tax	575.7	453.3	266.5	259.8	221.0
PBT Margin	18.8%	17.1%	11.0%	11.7%	11.6%
Tax	152.2	107.9	61.8	94.0	75.8
Net Profit	423.5	345.4	204.7	165.8	145.1
Net Profit Margin	13.8%	13.1%	8.4%	7.4%	7.6%
Other Comprehensive Income	2.4	1.6	-5.1	0.1	5.1
Total Comprehensive income for the period	425.9	347.0	199.6	165.9	150.2
EPS	8.5	6.9	4.1	3.3	2.9

<sup>1.</sup> Given the seasonality in the business, it is best monitored on an annual basis

<sup>2.</sup> Appointed date for merger of ECC and SCIL is 1st Apr'18

<sup>\*</sup> Revenue net of Excise Duty; \*\* Merger expenses

## Consolidated Balance Sheet



Assets (Rs. Crs)	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18
Non-Current Assets (A)	487.6	365.7	360.6	318.3	312.7
Property, Plant and Equipment	349.6	277.6	282.9	277.2	264.8
Capital work-in-progress	21.1	4.3	6.5	3.2	4.5
Right to use an Asset	36.4	31.1	34.9	-	-
Other Intangible Assets	4.3	0.6	1.7	2.1	1.9
Intangible Assets under Development	14.1	10.0	3.8	4.9	4.3
Non-Current Financial Assets					
(i) Investments	0.1	0.1	0.1	0.1	0.1
(ii) Loans & other financial assets	30.8	6.0	5.3	7.6	7.3
Deferred tax Asset (net)	-	-	1.1	-	-
Non-Current tax Assets (net)	21.6	18.5	20.2	18.8	24.8
Other non-current Assets	9.5	17.6	4.2	4.4	5.1
Current Assets (B)	2,522.0	2,304.3	1,745.6	1,541.7	1,345.7
Inventories	937.8	754.4	588.0	680.6	609.3
Current Financial Assets					
(i) Investments	356.02	290.2	86.0	-	-
(ii) Trade receivables	843.13	848.2	849.8	671.0	551.8
(iii) Cash and cash equivalents	57.25	213.3	92.6	50.5	73.5
(iv) Bank balances other than (iii) above	21.88	28.8	0.9	0.9	0.8
(v) Loans	0.47	7.7	7.9	5.1	3.7
(vi) Other financial assets	174.50	11.4	21.8	15.8	10.4
Other Current Assets	131.03	150.3	98.6	117.8	96.3
Total Assets (A+B)	3,009.6	2,670.1	2,106.2	1,860.0	1,658.4

Equity & Liabilities (Rs. Crs)	Mar-22	Mar-21	Mar-20	Mar-19	Mar-18
EQUITY (A)	1,927.2	1,541.3	1,221.8	1,048.4	954.0
Equity Share Capital	499.1	499.1	499.1	274.6	274.6
Other Equity	1428.1	1,042.2	722.6	773.8	679.4
Non-Current liabilities (B)	61.0	49.6	44.5	30.2	32.5
Non-current Financial liabilities					
Lease Liabilities	24.7	15.3	19.4	-	-
Provisions	22.3	29.2	25.1	15.6	12.7
Deferred tax liabilities (net)	13.9	5.0	-	14.6	18.1
Non-current Tax Liabilities	-	-	-	-	1.7
Current liabilities (C)	1,021.4	1,079.2	839.9	781.3	671.9
Current Financial liabilities					
(i) Borrowings	-	-	-	19.7	10.1
(ii) Trade Payables	517.2	598.3	490.9	480.8	527.3
(iii) Lease Liabilities	12.9	17.3	16.2	-	-
(iii) Other financial liabilities	399.7	349.8	235.4	179.2	55.6
Other current liabilities	79.8	108.2	80.2	87.2	70.1
Provisions	7.2	5.6	9.7	2.5	2.3
Current tax liabilities	4.7	0.0	7.4	12.0	6.6
Total Equity & Liabilities (A+B+C)	3,009.6	2,670.1	2,106.2	1,860.0	1,658.4

NIL borrowings
Cash, Cash Equivalents & Liquid Investments of ~Rs. 599 Crs as on 31st March 2022

<sup>1.</sup> Given the seasonality in the business, it is best monitored on an annual basis

<sup>2.</sup> Appointed date for merger of ECC and SCIL is 1st Apr'18

## Consolidated Working Capital Movement



Particulars (Rs. Crs)	Mar-22	Mar-21	Mar-20	Mar-19
Inventory (A)	937.8	754.4	588.0	680.6
Inventory Days (Inventories/ COGS*365) (i)	179	166	134	170
Trade Receivables (B)	843.1	848.2	849.8	671.0
Trade Receivables Days (Trade Receivables / Revenue*365) (ii)	100	117	128	110
Trade Payables (C)	517.2	598.3	490.9	480.8
Trade Payables Days (Trade Payables/ COGS*365) (iii)	99	132	111	120
Other Financial Liabilities (D)	399.7	349.8	235.4	179.2
Other Financial Liabilities Days (Other Current Liabilities / Revenue*365) (iv)	48	48	35	29
Net Working Capital (A+B-C-D)	864.0	654.5	711.4	691.6
Net Working Capital Days (i + ii – iii – iv)	133	103	115	131

<sup>1.</sup> Given the seasonality in the business, it is best monitored on an annual basis

<sup>2.</sup> Appointed date for merger of ECC and SCIL is 1st Apr'18

## Consolidated Cash Flow Statement



Particulars (Rs. Crs)	Year ended 31-Mar-22	Year ended 31-Mar-21	Year ended 31-Mar-20	Year ended 31-Mar19	Year ended 31-Mar-18
Net Profit Before Tax	575.7	453.3	266.5	259.8	221.0
Adjustments for: Non-Cash Items / Other Investment or Financial Items	46.3	54.5	45.7	18.6	9.6
Operating profit before working capital changes	622.0	507.8	312.2	278.5	230.6
Changes in working capital	-257.6	25.6	-9.4	-112.7	-100.0
Cash generated from Operations	364.4	533.4	302.8	165.8	130.6
Direct taxes paid (net of refund)	142.6	107.9	81.4	88.1	83.1
Net Cash from Operating Activities	221.8	425.4	221.4	77.7	47.4
Net Cash from Investing Activities	-290.2	-282.7	-117.9	-35.3	-39.6
Net Cash from Financing Activities	-62.6	-47.1	-61.4	-65.4	7.2
Net Increase /(Decrease) in Cash and Cash equivalents	-131.1	95.7	42.2	-23.1	15.0
Add: Cash & Cash equivalents at the beginning of the period	188.3	92.6	50.5	73.5	58.6
Cash & Cash equivalents at the end of the period	57.2	188.3	92.6	50.5	73.6

<sup>1.</sup> Given the seasonality in the business, it is best monitored on an annual basis since a significant portion of revenue & PAT is recorded in the first half of the year

<sup>2.</sup> Appointed date for merger of ECC and SCIL is 1st Apr'18

## Key Takeaways



# Formidable Player in the Indian Agro-chem Space

- Strong / leadership position across products and processes
- Ability to develop new combination products (9 under registrations and additional under development)

## Experienced Management Team and Board of Directors

- Strong management and autonomous Board with vast experience and domain expertise
- Localized experience enables better understanding of market needs to drive growth

#### Well-diversified Product Portfolio Across Agro-Chem Value Chain

- Multi-product, multi-geography, multi-customer de-risking
- Access to an impressive range of own actives along with significant exposure towards speciality products resulting in product offerings at all price points serving multiple customers sub-segment

# Strong Brand and Well-Entrenched Distribution Network

- 23 states, 60+ depots, 16,000+ distributors, 40,000+ dealer network
- High credibility and brand recall amongst famers and the trade on account of transparent and ethical business dealings

# To Benefit from Strong Parentage of SCC Japan

- Benefits from international standing of SCC Japan; most well revered brand renowned for its quality
- Access to SCC's global supply chain and global R&D activities (one of the largest spenders) resulting in development of actives and broad range of formulation research

## State-of-the-art Manufacturing and R&D Facilities

- Operates five manufacturing facilities with state-of-the-art plants at strategic location which helps reduce logistic time and costs
- Capacity not a constraint allowing for significant growth on existing investments
- Holds 27 patents and further 9 applications filed

## Strong Track Record of Driving Growth

- Grown 13X over FY11-22 driven by organic and inorganic expansion; 11% CAGR for merged entity (including Excel Crop Care) over the same period
- Debt free balance sheet with strong return ratios



## Glance of various events to bring people together



